skyrizi abbvie - Search News

AbbVie Jumps

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate

AbbVie stock surged early Friday after beating fourth-quarter expectations, largely on the back of its immunology drugs.

Hosted on MSN · 3h

AbbVie Surges 8% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.

MarketWatch · 5h

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker logged a loss of $22 million, or 2 cents a share, compared to earnings of $822 million, or 46 cents a share, a year earlier.

AbbVie forecasts 2025 profit above estimates

MarketWatch on MSN · 2h

AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to offset declining sales of its blockbuster Humira.

AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.

Wall Street Journal · 2h

AbbVie Stock Soars on Key Drugs’ Sales Forecasts

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall Street's estimates,

1hon MSN

AbbVie targets $24B in 2025 sales from Skyrizi and Rinvoq, outlines robust mid-single-digit growth

Q4 2024 Management View CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with ...

AbbVie jacks up 2027 sales projection for star duo of Skyrizi, Rinvoq to $31B

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

4h

AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

24/7 Wall St. on MSN57m

AbbVie (ABBV) Earnings Live: Why The Stock Is Up Big Today

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

1h

AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...

4h

AbbVie says ‘very pleased’ with progress in 2024, sees ‘strong growth’ in 2025

Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...

5hon MSN

AbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidance

AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results